Arrowhead Pharmaceuticals announced results for their RNAi obesity treatments, ARO-INHBE and ARO-ALK7. The main data point focuses on combining their drug with tirzepatide. Patients taking ARO-INHBE plus tirzepatide saw 9.4% weight loss at week 16, compared to 4.8% for those on tirzepatide alone. The combination also showed roughly triple the reduction in visceral and liver fat compared to tirzepatide monotherapy. They also released data for ARO-ALK7 showing it successfully reduced the target mRNA in fat tissue. Management is hosting a webinar today to go over the specific results.